Fate of 'BioShield' Bill for Anti-Terror Drugs Unclear

Congress this week is expected to take up a $6 billion bill for developing tests, treatments and vaccines against bioterrorism. Known as Project BioShield, the plan aims to create research incentives for the private sector. But many drug and biotech firms say without protections from potential lawsuits, the bill won't do much to stimulate drug development. Hear NPR's Julie Rovner.



Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

Support comes from: